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Mycobacterium microti is a member of the Mycobacte-
rium tuberculosis complex that causes pathology in many 
mammals. M. microti infections have been found in some 
countries in Europe. We report an outbreak of tuberculosis 
caused by M. microti in wild boars in Spain.
Mycobacterium microti is a member of the Mycobac-terium tuberculosis complex (MTBC), which also 
includes M. tuberculosis and M. bovis, the main causes of 
human and animal tuberculosis (TB), respectively. Even 
though voles and other wild small rodents were initially 
identified as its natural hosts (1), M. microti can cause pa-
thology in a wide range of mammals, including pets, live-
stock, wildlife (2–5), and humans (6). M. microti infections 
have been previously reported in several countries in Eu-
rope, including Switzerland, Italy, and France (3,7–9). We 
report an outbreak of tuberculosis caused by M. microti in 
free-ranging wild boars in the Iberian Peninsula in Spain. 
During June 2017–March 2019, a total of 9 free-rang-
ing wild boars with lesions associated with TB were de-
tected in the outbreak area, covering ≈3,000 hectares in the 
Catalan Pyrenees (Figure). TB was confirmed histologi-
cally, first by hematoxylin and eosin staining (9/9) and then 
by Ziehl-Neelsen staining of acid-fast bacilli (7/9). In all 
cases, submandibular lymph nodes showed granulomatous 
necrotizing lymphadenitis, sometimes with scant acid-fast 
bacilli, similar to that found in M. microti infections previ-
ously described in wild boar, which were generally con-
fined to lymph nodes in the head (7,8). 
To confirm the causative agent for these infections, we 
extracted DNA from tissue samples (DNAExtract-VK, Va-
cunek, http://vacunek.com) and performed real-time PCR 
(TBC-VK, Vacunek), which confirmed MTBC in 6 of 9 
suspected cases. DVR spoligotyping at VISAVET Health 
Surveillance Centre, Universidad Complutense de Madrid, 
identified the pathogen in 4 of the 6 confirmed MTBC cases 
as M. microti (spoligopattern SB0423; Mycobacterium bovis 
spoligotype database, http://www.mbovis.org). In the other 
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Figure. Outbreak area for wild boar tuberculosis (TB) cases, Spain, June 2017–March 2019. Circles show cases of wild boars with TB 
lesions. Stars indicate the location of cattle herds with positive skin tests (not confirmed at slaughterhouse); triangles, pentagons, and 
diamonds show locations of Mycobacterium tuberculosis complex–seropositive ungulates (no tissue samples were obtained from these 
animals). Colors indicate etiologic agent identification: red, M. microti; orange, any M. tuberculosis complex; yellow, unidentified. Different 
hunting areas are indicated. The border between Spain and France and the main village (Vielha) are labelled. Inset maps show location of the 
study area on the Iberian Peninsula. 
2 cases, the laboratory was unable to determine the species 
because of low DNA load from the sample. This result likely 
was due to the slow in vitro growth rate of M. microti in in-
fected animals, which makes it difficult to isolate in routine 
diagnostic laboratories. 
Spoligopattern SB0423 is included in a phylogenetic 
cluster with spoligopattern SB0112, also associated with M. 
microti, on the basis of neighbor joining. Both spoligotypes 
are localized in the eastern French Pyrenees, close to the bor-
ders with Spain and Andorra (3). Most M. microti cases in 
France, found in cats, dogs, and llamas during 2005–2016 
and, since 2015, in wild boars and badgers, have been found 
within 50 km of the outbreak area in Spain. The 2017 M. 
microti cases described in this report were found closer to 
the border with France; the remaining 2 cases, detected in 
2019, were localized near the southern limit of the outbreak 
area (Figure). 
In the outbreak area, up to 18 animals in 3 cattle herds 
showed positive results for a single intradermal tuberculin 
skin test (Figure). However, none of these animals showed 
gross lesions in target tissues (i.e., lungs, pulmonary, and 
retropharyngeal lymph nodes) at a slaughterhouse or posi-
tive results to mycobacterial culture and PCR. Similarly, in 
a recent case in France, a cow reacting to a TB skin test did 
not show TB-like lesions in respiratory tissues and returned 
negative results from cultures, but M. microti DNA was 
finally detected in retropharyngeal lymph nodes only by 
using advanced molecular techniques (5). These results in-
dicate that cattle exposed to M. microti may induce positive 
results to diagnostic tests performed in bovine TB eradica-
tion campaigns. M. microti infection can sometimes cause 
visible lesions in cattle (2), but the fact that M. microti are 
natural knockouts for the virulence-related RD1mic genomic 
region (10) may indicate a lower pathogenicity compared 
with other MTBC species and account for these negative 
test results. 
We tested additional wild ungulates in the outbreak 
area and found that 6 (2 red deer, 1 fallow deer, and 3 cham-
ois) were seropositive for MTBC using a MPB83-specific 
IgG indirect ELISA test (Figure). Unfortunately, no tissue 
samples were submitted to examine for lesions or to detect 
and identify mycobacteria. However, overall positive re-
sults for M. microti and the absence of other MTBC strains 
during the 2017–2019 period in the outbreak area suggest 
a multihost circulation of M. microti. Because voles are 
known maintenance hosts of M. microti (1), further inves-
tigation of wild small rodent populations in the outbreak 
area could determine the epidemiology of this outbreak in 
greater detail. 
These findings, together with previously reported cas-
es nearer the border between France and Spain, indicate 
a transboundary circulation of M. microti across the Pyre-
nean border that should be taken into account for wildlife 
TB surveillance. Coordinated action between animal health 
authorities and laboratories in Spain and France is required, 
as well as the improvement of livestock management and 
biosecurity practices. 
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We estimated the availability of the injectable antimicrobial 
drugs recommended for point-of-care treatment of gonor-
rhea and syphilis among US physicians who evaluated 
patients with sexually transmitted infections in 2016. Most 
physicians did not have these drugs available on-site. Fur-
ther research is needed to determine the reasons for the 
unavailability of these drugs.
Rates of sexually transmitted infections (STIs) are on the rise in the United States. Compared with the inci-
dence in 2013, the numbers of reported gonorrhea (+75%) 
and syphilis (primary and secondary, +153%) cases in 2017 
were dramatically increased (1). Timely (optimally same-
day) treatment of bacterial STIs with a highly effective 
regimen is critical for national STI control efforts and can 
help mitigate the development of drug resistance, a particu-
larly pertinent issue for Neisseria gonorrhoeae (2). In ad-
dition, the high number of congenital syphilis cases in the 
United States in 2017 highlights the need for efficient and 
effective treatment of Treponema pallidum infection (3).
The recommended first-line treatment for uncomplicat-
ed gonorrhea is intramuscular ceftriaxone (250 mg) and for 
primary and secondary syphilis is intramuscular penicillin G 
benzathine (2.5 million units) (4). On-site access to these in-
jectable medications in clinics facilitates point-of-care treat-
ment and helps mitigate drug resistance to N. gonorrhoeae 
and T. pallidum when these drugs are used instead of the oral 
antimicrobial drug alternatives. Therefore, we set out to de-
termine a nationally representative estimate of the availabil-
ity of these medications and examine if differences existed 
by geographic location and between offices designated and 
not designated as patient-centered medical homes (PCMHs).
We used the 2016 Physician Induction File of the Na-
tional Ambulatory Medical Care Survey (5) to assess the 
number of physicians who treat patients with STIs and had 
injectable antimicrobial drugs available on-site. The Phy-
sician Induction File is a nationally representative survey 
of office-based, nonfederal physicians in the United States 
and includes information regarding practice characteristics 
and habits. Use of the data is restricted, and access is fa-
cilitated through the Research Data Center, National Center 
for Health Statistics, Centers for Disease Control and Pre-
vention, in Hyattsville, Maryland, USA. A total of 1,030 
physicians (46.2% unweighted response rate), representing 
an estimated 330,581 (95% CI 326,994–334,168) physi-
cians in the United States, completed the Physician Induc-
tion File in 2016. In this survey, physicians who reported 
evaluating or treating patients for STIs were asked which 
antimicrobial drugs they had available on-site for same-
day management of gonorrhea and syphilis, including in-
tramuscular ceftriaxone and penicillin G benzathine at the 
recommended doses. We determined national estimates of 
reported on-site, same-day availability for these antimicro-
bial drugs and stratified results by PCMH designation and 
US region. We used multiple logistic regression models to 
determine if PCMH designation and region were predictive 
of on-site availability of these 2 medications.
An estimated 45.2% (149,483, 95% CI 138,850–
160,116) of office-based physicians indicated that they 
evaluate patients for STIs in their offices. Of these, 77.9% 
(116,479, 95% CI 105,360–127,598) reported not hav-
ing penicillin G benzathine available on-site and 56.1% 
(83,827, 95% CI 73,709–93,945) reported not having cef-
triaxone. Access to both of these drugs was generally high-
er in the South (Table). Physicians in offices not designated 
PCMHs were more likely than those in offices designated 
PCMHs to report lacking on-site availability of ceftriaxone 
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